NASDAQ:KRON

Kronos Bio Stock Forecast, Price & News

$21.56
-0.15 (-0.69 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.20
Now: $21.56
$21.93
50-Day Range
$21.71
MA: $28.14
$29.51
52-Week Range
$21.50
Now: $21.56
$39.60
Volume254,297 shs
Average Volume187,388 shs
Market Capitalization$1.21 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
Kronos Bio logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRON
CUSIPN/A
CIKN/A
Phone650-781-5200
Employees61
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$1.21 billion
Next Earnings Date6/22/2021 (Estimated)
OptionableNot Optionable

Headlines

Kronos Bio (NASDAQ:KRON) Trading Down 9.9%
April 14, 2021 |  americanbankingnews.com
Kronos Bio (NASDAQ:KRON) Sees Unusually-High Trading Volume
April 13, 2021 |  americanbankingnews.com
Kronos Bio (NASDAQ:KRON) Hits New 12-Month Low at $25.32
April 12, 2021 |  americanbankingnews.com
Kronos Bio (NASDAQ:KRON) Stock Price Down 3.8%
April 7, 2021 |  americanbankingnews.com
Kronos Bio (NASDAQ:KRON) Sees Strong Trading Volume
March 31, 2021 |  americanbankingnews.com
Kronos Bio (NASDAQ:KRON) Trading Down 7.7%
March 25, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.67 out of 5 stars

Medical Sector

314th out of 2,025 stocks

Pharmaceutical Preparations Industry

142nd out of 772 stocks

Analyst Opinion: 3.5Community Rank: 4.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
$21.56
-0.15 (-0.69 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRON News and Ratings via Email

Sign-up to receive the latest news and ratings for KRON and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kronos Bio (NASDAQ:KRON) Frequently Asked Questions

Is Kronos Bio a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kronos Bio in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kronos Bio stock.
View analyst ratings for Kronos Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Kronos Bio?

Wall Street analysts have given Kronos Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kronos Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Kronos Bio's next earnings date?

Kronos Bio is scheduled to release its next quarterly earnings announcement on Tuesday, June 22nd 2021.
View our earnings forecast for Kronos Bio
.

How were Kronos Bio's earnings last quarter?

Kronos Bio, Inc. (NASDAQ:KRON) issued its quarterly earnings results on Monday, March, 22nd. The company reported ($0.70) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.79) by $0.09.
View Kronos Bio's earnings history
.

What price target have analysts set for KRON?

4 brokers have issued 12 month target prices for Kronos Bio's shares. Their forecasts range from $36.00 to $50.00. On average, they anticipate Kronos Bio's stock price to reach $43.67 in the next twelve months. This suggests a possible upside of 102.5% from the stock's current price.
View analysts' price targets for Kronos Bio
or view top-rated stocks among Wall Street analysts.

Who are Kronos Bio's key executives?

Kronos Bio's management team includes the following people:
  • Dr. Norbert W. Bischofberger, Pres, CEO & Director (Age 65, Pay $280k)
  • Mr. Jorge F. DiMartino M.D., Ph.D., Chief Medical Officer & Exec. VP of Clinical Devel. (Age 58, Pay $398.27k)
  • Mr. Joshua A. Kazam, Co-Founder & Director (Age 44)
  • Dr. Yasir B. Al-Wakeel, CFO & Head of Corp. Devel. (Age 39)
  • Ms. Barbara A. Kosacz, COO & Gen. Counsel (Age 63)
  • Dr. Christopher Dinsmore, Chief Scientific Officer (Age 55)
  • Stephanie Yao, Exec. Director of Investor Relations & Corp. Communications
  • Dr. Pasit Phiasivongsa Ph.D., Sr. VP of Pharmaceutical Devel.
  • Mr. Charles Lin Ph.D., Sr. VP of Biology
  • Mr. David M. Tanen J.D., Sec. & Director (Age 50)

Who are some of Kronos Bio's key competitors?

When did Kronos Bio IPO?

(KRON) raised $175 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 10,300,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Jefferies, Cowen and Piper Sandler served as the underwriters for the IPO.

What is Kronos Bio's stock symbol?

Kronos Bio trades on the NASDAQ under the ticker symbol "KRON."

When did the company's lock-up period expire?

Kronos Bio's lock-up period expired on Wednesday, April 7th. Kronos Bio had issued 13,157,895 shares in its initial public offering on October 9th. The total size of the offering was $250,000,005 based on an initial share price of $19.00. Since the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.

How do I buy shares of Kronos Bio?

Shares of KRON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kronos Bio's stock price today?

One share of KRON stock can currently be purchased for approximately $21.56.

How much money does Kronos Bio make?

Kronos Bio has a market capitalization of $1.21 billion.

How many employees does Kronos Bio have?

Kronos Bio employs 61 workers across the globe.

What is Kronos Bio's official website?

The official website for Kronos Bio is kronosbio.com.

How can I contact Kronos Bio?

The company can be reached via phone at 650-781-5200 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.